TCGA-43-6143-01A-11R-1820-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.580
- MITOTIC_SPINDLE+0.470
- MYC_TARGETS_V1+0.450
- MYC_TARGETS_V2+0.450
- SPERMATOGENESIS+0.260
- DNA_REPAIR+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.190
- WNT_BETA_CATENIN_SIGNALING+0.170
- MTORC1_SIGNALING+0.090
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.520
- IL6_JAK_STAT3_SIGNALING-0.510
- ALLOGRAFT_REJECTION-0.500
- TNFA_SIGNALING_VIA_NFKB-0.440
- COAGULATION-0.430
- PANCREAS_BETA_CELLS-0.430
- COMPLEMENT-0.390
- IL2_STAT5_SIGNALING-0.370
- ANGIOGENESIS-0.360
- KRAS_SIGNALING_UP-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.943 |
| 2 | TCGA-33-4587-01A-11R-2125-07 | — | cohortMD1 | 0.934 |
| 3 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.924 |
| 4 | MNG704 | — | — | 0.922 |
| 5 | BS_53M8PP88 | EPN | EPN Tumor | 0.918 |
| 6 | TCGA-77-A5G6-01A-11R-A27Q-07 | — | cohortSQ1 | 0.917 |
| 7 | TCGA-91-6847-01A-11R-1949-07 | — | cohortMD1 | 0.910 |
| 8 | SRR8518295 | — | E | 0.905 |
| 9 | SRR8518239 | — | E | 0.905 |
| 10 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.580 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |